Falco Selects PPD to Investigate Role of Biomarkers
Complete the form below to unlock access to ALL audio articles.
Falco biosystems Ltd. and PPD, Inc. have announced that they have signed an agreement under which PPD's biomarker discovery sciences group will seek to discover and validate biomarkers that may lead to the development of a diagnostic test for renal cell carcinoma.
Under the terms of the agreement, PPD will apply its proprietary, integrated platform for proteomics, peptidomics and metabolomics to identify biomarkers for renal cell carcinoma using samples obtained from a clinical study designed to optimize discovery of useful biomarkers for renal cell carcinoma.
PPD will own any intellectual property derived from these analyses, and Falco will receive an exclusive license to use such intellectual property in specified countries.
PPD's technology allows for the identification of biomarkers that may have a useful role in disease detection and in the evaluation of therapeutic response.
